EGFR and non-small cell lung carcinoma: The therascreen EGFR RGQ PCR Kit (Qiagen Co., Ltd., Hilden, Germany) is developed based on real-time PCR for the detection of 21 EGFR mutations located in exons 18–21; this commercial kit has been approved as a companion diagnosis for NSCLC by the United States Food and Drug Administration [9,10].